Wall Street analysts expect that Loxo Oncology Inc (NASDAQ:LOXO) will report $23.30 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Loxo Oncology’s earnings, with the highest sales estimate coming in at $25.00 million and the lowest estimate coming in at $21.60 million. The business is scheduled to issue its next quarterly earnings results on Tuesday, May 8th.
According to Zacks, analysts expect that Loxo Oncology will report full-year sales of $23.30 million for the current fiscal year, with estimates ranging from $2.90 million to $363.10 million. For the next financial year, analysts forecast that the firm will report sales of $161.46 million per share, with estimates ranging from $15.60 million to $272.20 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Loxo Oncology.
Loxo Oncology (NASDAQ:LOXO) last posted its quarterly earnings data on Thursday, March 1st. The biopharmaceutical company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($1.22) by $0.53. The company had revenue of $21.30 million during the quarter.
In other Loxo Oncology news, CEO Joshua H. Bilenker sold 15,000 shares of Loxo Oncology stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $81.12, for a total value of $1,216,800.00. Following the transaction, the chief executive officer now owns 190,207 shares of the company’s stock, valued at $15,429,591.84. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Jennifer Burstein sold 1,700 shares of Loxo Oncology stock in a transaction that occurred on Thursday, December 14th. The shares were sold at an average price of $83.27, for a total transaction of $141,559.00. Following the completion of the transaction, the vice president now directly owns 1,700 shares in the company, valued at approximately $141,559. The disclosure for this sale can be found here. Insiders have sold a total of 334,146 shares of company stock worth $27,668,728 in the last three months. 27.80% of the stock is owned by insiders.
Institutional investors and hedge funds have recently made changes to their positions in the business. Quantbot Technologies LP bought a new position in Loxo Oncology in the third quarter valued at approximately $122,000. QS Investors LLC bought a new position in Loxo Oncology in the fourth quarter valued at approximately $118,000. Cambridge Investment Research Advisors Inc. bought a new position in Loxo Oncology in the third quarter valued at approximately $212,000. Xact Kapitalforvaltning AB bought a new position in Loxo Oncology in the fourth quarter valued at approximately $208,000. Finally, Amalgamated Bank bought a new position in Loxo Oncology in the third quarter valued at approximately $268,000.
Loxo Oncology (NASDAQ:LOXO) opened at $132.87 on Wednesday. Loxo Oncology has a one year low of $40.52 and a one year high of $135.74.
ILLEGAL ACTIVITY NOTICE: “$23.30 Million in Sales Expected for Loxo Oncology Inc (LOXO) This Quarter” was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/03/14/23-30-million-in-sales-expected-for-loxo-oncology-inc-loxo-this-quarter.html.
Loxo Oncology Company Profile
Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.